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SIGNIFICANCE
Actinic keratoses, which are common precancerous lesions 
of the skin, arise from chronic lifetime sun exposure. A 
useful treatment method is photodynamic therapy (PDT), 
but this can cause strong pain during treatment. This study 
compared PDT using an alternative illumination source, 
pulsed dye laser, with conventional PDT in 60 patients with 
multiple actinic keratoses, in a randomized split-face de-
sign. Laser treatment was significantly less painful; howe-
ver, in contrast to previous research, it was less effective 
than conventional PDT, with a complete clearance rate of 
10% at 6 months in the laser treatment group compared 
with 45% in the conventional treatment group.
Previous research presents pulsed dye laser-mediated 
photodynamic therapy as a promising alternative to 
conventional red-light photodynamic therapy. In this 
study, 60 patients with 2 or more actinic keratoses 
randomly received either of these treatments on each 
side of the head. A physician blinded to the treatment 
evaluated treatment response at 6 months for each 
lesion, as completely, partially or not healed. Signi-
ficantly lower complete clearance rates (10.3% vs 
44.9%) and lesion-specific complete clearance rates 
were found for pulsed dye laser-mediated photodyna-
mic therapy (47.9%) vs conventional red-light photo-
dynamic therapy (73.4%). Significantly lower pain 
scores were found for pulsed dye laser-mediated photo-
dynamic therapy, with a mean numerical rating of 2.3, 
compared with 4.1 for conventional red-light photo-
dynamic therapy. The study population had a mean 
of 7.9 lesions, and 78% of patients had been treat ed 
previously for actinic keratoses on the treatment area. 
To conclude, in a population with severe sun dam-
age, pulsed dye laser-mediated photodynamic therapy 
seems less effective than conventional red-light photo-
dynamic therapy. Pulsed dye laser-mediated photo-
dynamic therapy may still be a treatment option for 
patients who are not compliant with conventional red-
light photodynamic therapy.
Key words: actinic keratosis; photochemotherapy; lasers; dye.
Accepted Jan 21, 2021; Epub ahead of print Jan 25, 2021
Acta Derm Venereol 2021; 101: adv00404.
Corr: Vivian Lindholm, Department of Dermatology and Allergology, Skin 
and Allergy Hospital, Helsinki University Hospital, Meilahdentie 2, FIN-
00250, Helsinki, Finland. E-mail: vivian.lindholm@helsinki.fi
Actinic keratoses (AKs) are common premalignant lesions of the skin that have a risk of developing 
into invasive squamous cell carcinoma (SCC) (1, 2). 
AK favour sun-exposed areas, such as the head, as 
chronic sun exposure increases their risk as well as high 
age, fair skin and immunosuppressive medication (3). 
Photodynamic therapy (PDT) is considered a first-line 
treatment for patients with multiple AKs (4). In PDT, a 
light-sensitizer containing a substrate of protoporphyrin 
IX (PpIX) is applied to the skin. PpIX then accumulates 
in transformed cells more than in the surrounding healthy 
cells, and the subsequent illumination causes an oxygen 
radical reaction in the tumour cells, which destroys the 
cells (5). Previous studies have found the treatment re-
sponse of PDT to be excellent, with clearance achieved 
in 89–92% of cases (6, 7). However, PDT can cause 
strong pain during treatment and is laborious both for 
the patient and the hospital, introducing a need for less 
painful and less time-consuming treatment options. Pre-
viously, 585-nm pulsed laser-mediated PDT (PDL-PDT) 
was introduced as an alternative light source for PDT 
because of a peak in the light absorption of PpIX in the 
585-nm light range (8). Previous studies suggest that 
PDL-PDT serves as a nearly or equally as effective and 
less painful treatment option than conventional PDT 
(cPDT), but the evidence is scarce. To our knowledge, 
there are 4 published studies, which are mostly limited 
by a short follow-up, small sample size, non-blinded or 
non-randomized designs (8–11). 
MATERIALS AND METHODS
This 6-month prospective study at the Helsinki University Hospital 
(HUS) Skin and Allergy Hospital in 2018 to 2020 included 60 pa-
tients with at least 2 AKs distributed symmetrically on both sides of 
either the scalp, forehead or cheeks. Using simple randomization, 
patients randomly received PDL-PDT treatment for all the lesions 
on half of the head and cPDT as control treatment on all lesions on 
the other half. For patients with extensive field cancerization, the 
treatment field was split into 2 parts, treated with either PDL-PDT 
or cPDT. Study patients were recruited from patients who were 
seen for follow-ups at the clinic due to recurrent skin tumours or 
premalignancies, or from patients referred to the clinic because 
of multiple AKs on the head. The study included patients over 18 
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years of age with Fitzpatrick skin types I to III (12). Exclusion 
criteria were: suspicion of pigmented AK, in-situ carcinomas, skin 
cancers, psoriasis or seborrhoeic eczema on the treatment area. 
Patients were invited to a 6-month follow-up appointment. For 
15 patients, the follow-up was postponed to 9 months because of 
the COVID-19 epidemic. One patient was not able to attend the 
6-month follow-up, and one was excluded early from the analyses 
because they were given the wrong treatment parameters. Thus, 
the final analyses included 58 patients. 
At the first appointment, the treatment area was photographed, 
a physician numbered the lesions, marked them on a plastic sheet 
to specify their location, and graded their severity on the Olsen 
scale, from I to III (13). After curettage and haemostasis with 
aluminium chloride, a light-sensitizer (methyl aminolaevulinate 
cream, Metvix®, Galderma, La Tour-de-Peilz, Switzerland) was 
applied in a layer 1-mm thick on the lesions and covered with an 
occlusive plastic foil for 2–3-h incubation. Before treatment, a 
local lidocaine anaesthetic spray was applied. The PDL-PDT-–
treated lesions were illuminated with 30% overlapping pulsed 
laser double-stacked pulses (Candela Vbeam perfecta® (Wayland, 
MA, USA), energy 7 J/cm2, spot size 7 mm, pulse duration 10 
ms, wavelength 595 nm and dynamic cooling 2/3) and the cPDT-
treated lesions with a red LED light for 7–8 min (Actilite® CL 128 
(Galderma), exposure 75 J/cm2, wavelength 630 nm). The side of 
the head not being treated was covered with aluminium foil during 
illumination. All patients were asked to evaluate the maximal 
pain during both illuminations on a 1–10 numerical rating scale 
(NRS). If needed, additional injection (n = 1) or regional (n = 1) 
nerve block anaesthesia with lidocaine was used. These patients 
were excluded from the pain analyses. 
At the follow-up appointment, a blinded investigator evaluated 
the treatment results for each treated lesion. For lesions that did 
not heal, the physician planned their further care. Only persistent 
lesions were documented, but not new untreated ones outside the 
treatment field. All the recruited volunteer patients were informed 
of the evaluations orally and in writing, and provided written 
consent. The study protocol was approved by the HUS ethics 
review committee. 
Statistical methods
The results are presented as patient complete clearance rates (CC), 
defined as all treated lesions of the patient in the corresponding 
treatment completely healed; and partial clearance rates (PC), 
defined as 75% of lesions of the patient in the treatment completely 
healed. In addition, the lesion-specific clearance rates (LSC), refer-
ring to the proportion of individual lesions that were completely, 
partially or not healed in both treatments, are presented. Cross-
tabulation combined with McNemar’s test was used for the CC 
and PC analyses and Pearson’s χ2 and Cochran–Armitage trend 
tests for the LSC analyses. Confounding factors were determined 
using Student’s t-test and Mann–Whitney U test. For the pain 
calculations, the paired t-test was used. The analyses were per-
formed using NCSS statistical software 12.09 (NCSS, Kaysville, 
UT, USA). Significance was set at p < 0.05. 
RESULTS
Baseline characteristics
The mean age of the study population was 77.0 years; 
there were 7 women and 52 men. Five had immuno-
suppressive medication, one had azathioprine and one 
metho trexate combined with prednisolone, 2 predni-
solone alone and one abiraterone acetate. None of the 
patients was an organ transplantation patient. The scalp 
was the most common treatment area (70%). The study 
population had either a mean of 7.9 individual lesions 
(mean 3.4 PDL-PDT-treated lesions and 3.5 cPDT-treated 
lesions) or one large field treatment area, without separate 
individual lesions (n = 10, 17%). A total of 25 patients had 
PDL-PDT treatment on all lesions on the left side of the 
head and 34 patients on the right side of the head. A total 
of 397 lesions were treated; 194 lesions with PDL-PDT 
and 203 with cPDT. One field treatment area is counted 
here as 1 AK. Thirteen patients had no previous treatment 
for AKs on the treatment area (Table I). 
Complete and partial clearance rates
A statistically significant difference (p < 0.00) was obser-
ved in the treatment response, with complete clearance 
achieved in 10.3% of patients with PDL-PDT treatment 
and 44.9% with cPDT (Table I). Regarding partial clea-
rance, the corresponding values were 29.3% in PDL-PDT 
and 60.3% in cPDT (p < 0.00) (Fig. 1). 
Lesion-specific clearance rates
The lesion-specific clearance rates for both treatments 
differed significantly (p < 0.00, Fig. 2). In PDL-PDT, 
47.9% of the lesions healed completely and 32.5% hea-
led partially; correspondingly for cPDT, 73.4% healed 
completely and 21.7% healed partially. Thus, 19.6% of 
Table I. Baseline characteristics
Patient characteristics
Patients in total, n 59








Immunosuppression, n (%) 5 (8)
Patients with field treatment, n (%) 10 (17)




Treatment historya, n (%)
No treatment 13 (22)
Cryotherapy 43 (73)
Topical treatment 24 (41)
Photodynamic therapy 19 (32)
Lesion characteristics
Lesions in total, n 397




Treatment, n (%) 
PDL-PDTb 194 (49)
cPDTc 203 (51)
Residual lesiond, n (%) 105 (26)
aPrevious treatment for AKs on the treatment area. bPulsed dye laser-mediated 
photodynamic therapy. cConventional photodynamic therapy.  dKnown residual 
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PDL-PDT-treated lesions and 4.9% cPDT-treated lesions 
did not heal (Fig. 2). No significant confounding factors 
were observed when adjusting for age, sex, skin type, 
lesion grade, residuals, previous treatment on the area, 
treatment area and immunosuppression (p > 0.9). No 
SCCs or in situ carcinomas arose on the treatment area 
during the 6-month follow-up.
Secondary outcomes
A significantly lower treatment response was found in 
PDL-PDT for thin lesions (grade I, n = 304). However, 
for thick lesions (grades II–III, n = 93), no significant dif-
ference was observed (p = 0.26) with 50.0% of the lesions 
healed in PDL-PDT vs 61.0% in cPDT. A significantly 
lower treatment response was observed in PDL-PDT 
compared with cPDT irrespective of the previous treat-
ment history of the area (p < 0.00 if no previous treatment, 
p = 0.02 if previous cryotherapy, and p < 0.00 if previous 
field treatment on the area).
Treatment tolerability
A significantly lower pain rate (p < 0.00) was observed 
in PDL-PDT treatment, with a mean pain score (NRS) 
of 2.3, and NRS 4.1 in cPDT. The eta coefficient showed 
a weak correlation between pain and CC (0.28) and a 
negligible correlation between pain and PC (0.18), im-
plying that pain contributes to 8% of the variance in the 
complete clearance rates and 3% of the variance in the 
partial clearance rates (Fig. 3).
DISCUSSION
Only a few studies have investigated the efficacy of PDL-
PDT in the treatment of AKs. Kessel et al. concluded no 
significant difference comparing PDL-PDT with cPDT 
in a split-face manner on 57 patients (9). At 6 months, 
62% of PDL-PDT-treated and 64% of cPDT-treated AKs 
had healed, and at 12 months, the corresponding values 
were 48% and 56%. The study limitations included a 
non-blinded investigation and a non-randomized study 
design, and newly developed lesions were not differen-
tiated from persistent ones, as in our study.
Alexiades-Armenakas et al. (10) treated 41 patients 
with AKs with PDL-PDT. In these patients, 90% of the 
PDL-PDT-treated lesions had healed at 8 months, 0% in 
the laser-only control group. Only 10 patients completed 
the follow-up of 8 months, limiting the reliability of the 
results. Kim et al. (11) treated 30 patients with PDL-PDT 
with a limited 3-month follow-up. The lesion complete 
clearance rates were 67% for PDL-PDT and 73% for 
cPDT, with a non-significant difference. The lesions were 
treated up to 5 times at 1–2 weeks apart. Karrer et al. (8) 
treated 24 patients. The lesion complete clearance rates 
for both treatments were 79% vs 84%, but the follow-up 
was limited to one month. At our clinic, a prior licentiate 
thesis on 51 lesions treated with PDL-PDT and 86 with 
cPDT, showed complete clearance for 71% of lesions 
treated with PDL-PDT vs 90% for cPDT at a 6-month 
Fig. 1. Complete and partial (75%) clearance rates (n (%)) in 
pulsed dye laser-mediated photodynamic therapy (PDL-PDT) and 
conventional photodynamic therapy (cPDT) differed significantly 
(p < 0.00).
Fig. 2. Lesion-specific clearance rates (n (%)) in pulsed dye laser-
mediated photodynamic therapy (PDL-PDT) and conventional 
photodynamic therapy (cPDT) with a significant difference (p < 0.00).
Fig. 3. Boxplot of the mean values for patient-reported pain on 
the numerical rating scale (NRS) in pulsed dye laser-mediated 
photodynamic therapy (PDL-PDT) and conventional photodynamic 
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follow-up (14). In this study, both treatments were re-
peated after 2 weeks. In all previous studies, PDL-PDT 
has a lower clearance rate, but it is mostly statistically 
insignificant. Our PDL-PDT lesion clearance rates are 
the weakest, with a clearance rate of 48% at 6 months 
compared with 62–92% in previous studies. However, in 
Alexiades-Armenakas et al. (10), the patients’ complete 
clearance rate for extremity lesions was also low (17% 
compared with 10% in our study). 
Mutually, in all previous studies, PDL-PDT caused 
significantly less pain during treatment than cPDT. Pain 
on the visual analogue scale (VAS) in these studies was 
1.7–2.6 in PDL-PDT and 4.2–6.5 for cPDT. Our cor-
responding mean NRS values of 2.3 and 4.1 are in line 
with the previous results.
For PDL-PDT treatment, the same laser parameters 
were used as in the study by Kessel et al. (9). The other 
studies’ parameters were also similar; however, Karrer 
et al. (8) used a higher 18 J/m2 fluence, Alexiades-
Armenakas et al. (10) and Ruohoalho et al. (14) a larger 
spot size 10 and Kim et al. (11) and Karrer et al. (8) a 
PDL-PDT wavelength of 585 nm. A weak or negligible 
association was found between pain values and out-
come (CC/PC). An association could suggest that the 
biological dose achieved in PDL-PDT is lower than in 
cPDT. However, since PDL-PDT pulses are of a short 
10 ms duration compared with 433 s in cPDT, it may 
not be adequate to evaluate treatment efficacy by the 
experienced pain. When comparing light doses in both 
treatments, it is lower in PDL-PDT, with 18.2 J/cm2 
(7 J/cm2 × 2 × 1.3) compared with 37 J/cm2 in cPDT (15), 
which suggests that additionally doubling the PDL-PDT 
dose could improve the treatment outcome. In addition, 
PpIX adsorption is higher at the 630 nm wavelength in 
cPDT compared with the 595 nm in PDL-PDT (15). 
Thus, PDL-PDT at 585 nm could be more effective, as 
was also concluded by Karrer et al. (8). Some studies (11, 
14) used multiple treatments 1–2 weeks apart, achieving 
higher clearance rates. However, a need for multiple 
treatments would give PDL-PDT a major disadvantage 
compared with cPDT; based on previous studies cPDT 
needs one treatment only for AKs (7). Other downsides 
to PDL-PDT treatment include relatively high costs if 
the clinic does not currently have a PDL laser device, 
and operating the device requires expertise.
The current study also shows low clearance rates for 
the cPDT-treated lesions, with a lesion clearance rate of 
73% vs 56–90% in previous studies. The clearance rates 
were low, even though we differentiated new lesions from 
persistent ones at follow-up. The study population was 
mostly severely sun-damaged, which could considerably 
impact the treatment efficacy. Most of the study patients 
were attending regular follow-ups at our clinic because of 
recurrent skin cancers and their precursors. Of the study 
patients, 78% already had previous treatment for AKs on 
the treatment area. The mean lesion count in patients was 
high, at 7.9, and 17% of the patients received treatment 
for one large field cancerization area. The mean age of 
the patients, 77.0 years, was higher than in all previous 
studies (70–73.7). These severely sun-damaged patients 
are most probably more difficult to treat successfully.
No statistically significant difference was observed in 
the treatment response for PDL-PDT and cPDT regarding 
the thicker lesions in grades II–III. However, a lower 
proportion of only 50% of lesions healed in PDL-PDT 
vs 61% in cPDT. Not achieving statistical significance 
could be due to a lower number of lesions in grades II–III 
(n = 93) than grade I (n = 304). In addition, treatment ef-
ficacy is lower overall for thicker lesions, decreasing the 
possibility of achieving statistical significance.
A limitation of this study is that patients were not blind-
ed to the treatment they received. However, this would 
be difficult to overcome due to the obvious differences 
between the 2 illumination methods. The follow-up is 
rather short, but it is planned to extend the follow-up to 2 
years. A further limitation was not to document the mean 
illumination lengths of the 2 treatment methods or the 
post-treatment skin reactions. However, the advantages 
of PDL-PDT treatment regarding these factors have 
clearly been shown in previous research, where PDL-
PDT has been found to be faster and less laborious, and 
the skin reactions less extensive (9, 10). 
This study has a number of major strengths; it has a 
half-side comparative design, which limits biases, as the 
patients serve as their own controls. In addition, a blinded 
investigation is a major strength, as well as the adequate 
number of study patients and treated lesions. A further 
strength is that the treated lesions are strictly defined 
by location, so that new lesions are easily differentiated 
from persistent ones at the follow-up appointment. In 
clinical work, as advised by current guidelines (16), 
we recommend treating the whole photodamaged area 
at once, although most patients in this study have been 
treated for distinct lesions. This treatment regimen was 
chosen to increase the reliability of the study.
This half-side comparative study shows significantly 
inferior treatment results for PDL-PDT compared with 
cPDT in a severely sun-damaged population. However, 
PDL-PDT could serve as a treatment option for patients 
who are not compliant with cPDT due to its tolerability 
issues. There is a need for further randomized, compa-
rative and blinded studies on PDL-PDT in the treatment 
of AKs, preferably on a less sun-damaged population, 
to ascertain the usability of PDL-PDT. In addition, the 
most efficient laser parameters and treatment parameters 
should be determined in further research. 
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